Galapagos appoints Chief Medical Officer

Galapagos has appointed Dr. Walid Abi-Saab as a Chief Medical Officer (CMO), who came from Shire Pharmaceuticals, beginning on March 1, 2017.

The Dr Abi-Saab will be a member of the Executive Committee and drive the overall medical strategy of the company. The CMO has responsibility for late stage clinical development and operations, medical and regulatory affairs, and safety. He will be a key participant in the company’s strategic planning, partnering discussions, and presentations to investors and other stakeholders, Galapagos said in its press release on Wednesday.

Previously, Abi-Saab was with Shire Pharmaceuticals where he held various clinical development leadership roles, most recently as Group Vice President, Global Clinical Development – Therapeutic Area Head, Gastro-intestinal, Endocrinology and Metabolism. Prior to that, he led clinical development activities at Novartis, Abbott Laboratories, and Pfizer, addressing a wide range of therapeutic areas and leading teams throughout the clinical development process.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.